Q3 EPS Estimates for HealthEquity Boosted by Zacks Research

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Investment analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for HealthEquity in a research report issued to clients and investors on Monday, July 14th. Zacks Research analyst R. Department now anticipates that the company will earn $0.74 per share for the quarter, up from their prior estimate of $0.73. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share. Zacks Research also issued estimates for HealthEquity's Q2 2027 earnings at $0.94 EPS, Q4 2027 earnings at $0.94 EPS, FY2027 earnings at $3.56 EPS, Q1 2028 earnings at $0.98 EPS and FY2028 earnings at $3.96 EPS.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. HealthEquity had a return on equity of 11.01% and a net margin of 9.80%. The firm had revenue of $330.80 million for the quarter, compared to the consensus estimate of $322.25 million. During the same quarter last year, the business posted $0.80 earnings per share.

A number of other brokerages have also recently weighed in on HQY. Barrington Research lifted their price objective on HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a research note on Thursday, June 5th. KeyCorp dropped their price objective on HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. JMP Securities lifted their price objective on HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a research note on Wednesday, June 4th. Wall Street Zen raised HealthEquity from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Royal Bank Of Canada lifted their price objective on HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a research note on Wednesday, June 4th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $118.55.

HealthEquity Trading Down 2.4%

HQY stock traded down $2.42 during midday trading on Thursday, hitting $97.70. 623,415 shares of the company's stock were exchanged, compared to its average volume of 871,681. The business has a 50-day simple moving average of $101.65 and a two-hundred day simple moving average of $98.49. The company has a current ratio of 4.06, a quick ratio of 4.06 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $8.45 billion, a PE ratio of 71.31, a P/E/G ratio of 1.51 and a beta of 0.49. HealthEquity has a 1-year low of $65.01 and a 1-year high of $116.65.

Insider Buying and Selling

In other news, EVP Elimelech Rosner sold 58,000 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $112.56, for a total value of $6,528,480.00. Following the sale, the executive vice president directly owned 75,689 shares in the company, valued at $8,519,553.84. This represents a 43.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jon Kessler sold 97,767 shares of the stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.05, for a total value of $10,954,792.35. Following the sale, the director owned 75,000 shares in the company, valued at approximately $8,403,750. This trade represents a 56.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 291,744 shares of company stock worth $32,705,007 in the last quarter. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On HealthEquity

Hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its position in HealthEquity by 232.4% during the second quarter. Farther Finance Advisors LLC now owns 246 shares of the company's stock valued at $26,000 after acquiring an additional 172 shares during the period. Versant Capital Management Inc purchased a new stake in HealthEquity during the first quarter valued at about $28,000. WPG Advisers LLC purchased a new stake in HealthEquity during the first quarter valued at about $28,000. Transce3nd LLC purchased a new stake in HealthEquity during the fourth quarter valued at about $29,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of HealthEquity during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 99.55% of the company's stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.